Early safety test for new drug in people with liver problems
NCT ID NCT06619054
Summary
This early-stage study tested how a single dose of an investigational drug, KP-001, is processed by the body in people with different levels of liver impairment compared to healthy people. The goal was to understand if liver problems change how the drug works or its safety. The study involved 24 adult participants, some with healthy livers and others with mild to severe liver damage.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sites contracted by Parexel
San Antonio, Texas, 08103, United States
Conditions
Explore the condition pages connected to this study.